176 related articles for article (PubMed ID: 28467615)
1. Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS study.
Reiser M; Borte M; Huscher D; Baumann U; Pittrow D; Sommer C; Stangel M; Fasshauer M; Gold R; Hensel M
Eur J Haematol; 2017 Aug; 99(2):169-177. PubMed ID: 28467615
[TBL] [Abstract][Full Text] [Related]
2. [Immunoglobulins in PID, SID and neurological autoimmune disease].
Borte M; Baumann U; Pittrow D; Hensel M; Fasshauer M; Huscher D; Reiser M; Stangel M; Gold R; Kirch W;
Dtsch Med Wochenschr; 2012 Mar; 137(13):675-80. PubMed ID: 22434180
[TBL] [Abstract][Full Text] [Related]
3. [Subcutaneous immunoglobulin and support program: what level of interest of patients?].
Bourdin A; Berger J; Früh A; Spertini F; Bugnon O
Rev Med Suisse; 2015 Apr; 11(469):831-5. PubMed ID: 26040165
[TBL] [Abstract][Full Text] [Related]
4. [Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution].
Haddad L; Perrinet M; Parent D; Leroy-Cotteau A; Toguyeni E; Condette-Wojtasik G; Hachulla E
Rev Med Interne; 2006 Dec; 27(12):924-6. PubMed ID: 17011081
[TBL] [Abstract][Full Text] [Related]
5. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
Wasserman RL
Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
[TBL] [Abstract][Full Text] [Related]
6. A French observational study describing the use of human polyvalent immunoglobulins in hematological malignancy-associated secondary immunodeficiency.
Benbrahim O; Viallard JF; Choquet S; Royer B; Bauduer F; Decaux O; Crave JC; Fardini Y; Clerson P; Lévy V
Eur J Haematol; 2018 Jul; 101(1):48-56. PubMed ID: 29644723
[TBL] [Abstract][Full Text] [Related]
7. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy.
Chapel HM; Spickett GP; Ericson D; Engl W; Eibl MM; Bjorkander J
J Clin Immunol; 2000 Mar; 20(2):94-100. PubMed ID: 10821460
[TBL] [Abstract][Full Text] [Related]
8. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
McCormack PL
BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin treatment in primary antibody deficiency.
Maarschalk-Ellerbroek LJ; Hoepelman IM; Ellerbroek PM
Int J Antimicrob Agents; 2011 May; 37(5):396-404. PubMed ID: 21276714
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
[TBL] [Abstract][Full Text] [Related]
11. [Educational program for doctors and nurses taking care for primary immunodeficiency patients treated with subcutaneous immunoglobulins].
Lewandowicz-Uszyńska A; Szaflarska A; Pietrucha B; Tarnowska I
Pol Merkur Lekarski; 2011 Jun; 30(180):452-7. PubMed ID: 21751558
[TBL] [Abstract][Full Text] [Related]
12. [Use of intravenous and subcutaneous human immunoglobulins].
Ramus B; Benbrahim O; Chérin P
Soins; 2019 Mar; 64(833):13-18. PubMed ID: 30879622
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study.
Vultaggio A; Azzari C; Milito C; Finocchi A; Toppino C; Spadaro G; Trizzino A; Baldassarre M; Paganelli R; Moschese V; Soresina A; Matucci A
Clin Drug Investig; 2015 Mar; 35(3):179-85. PubMed ID: 25672929
[TBL] [Abstract][Full Text] [Related]
15. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
Berger M; Murphy E; Riley P; Bergman GE;
South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of hemolytic reactions on the same day as immune globulin product administrations during 2008 to 2014.
Sridhar G; Ekezue BF; Izurieta HS; Forshee RA; Selvam N; Mintz PD; Anderson SA; Menis MD
Transfusion; 2018 Jan; 58(1):70-80. PubMed ID: 29119575
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin Replacement Therapy for Primary Immunodeficiency.
Sriaroon P; Ballow M
Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315
[TBL] [Abstract][Full Text] [Related]
18. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies.
Na IK; Buckland M; Agostini C; Edgar JDM; Friman V; Michallet M; Sánchez-Ramón S; Scheibenbogen C; Quinti I
Eur J Haematol; 2019 Jun; 102(6):447-456. PubMed ID: 30801785
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of patients with primary antibody deficiencies in Germany].
Borte M; Oertelt C; Högy B
Klin Padiatr; 2005; 217(5):276-80. PubMed ID: 16167275
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability.
Wasserman RL; Melamed I; Kobrynski L; Puck J; Gupta S; Doralt J; Sharkhawy M; Engl W; Leibl H; Gelmont D; Yel L
Immunotherapy; 2016 Oct; 8(10):1175-86. PubMed ID: 27468136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
